Hyperglycaemia and risk of adverse perinatal outcomes:systematic review and meta-analysis by Farrar, Diane et al.
                          Farrar, D., Simmonds, M., Bryant, M., Sheldon, T. A., Tuffnell, D., Golder,
S., ... Lawlor, D. A. (2016). Hyperglycaemia and risk of adverse perinatal
outcomes: systematic review and meta-analysis. BMJ, 354, [i4694]. DOI:
10.1136/bmj.i4694
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1136/bmj.i4694
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMJ at
http://www.bmj.com/content/354/bmj.i4694. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
the bmj | BMJ 2016;354:i4694 | doi: 10.1136/bmj.i4694
RESEARCH
1
open access
For numbered affiliations see 
end of article.
Correspondence to:  
Diane.Farrar@bthft.nhs.uk
Additional material is published 
online only. To view please visit 
the journal online.
Cite this as: BMJ 2016;354:i4694
http://dx.doi.org/10.1136/bmj.i4694
Accepted: 15 August 2016
Hyperglycaemia and risk of adverse perinatal outcomes: 
systematic review and meta-analysis
Diane Farrar,1,2 Mark Simmonds,3 Maria Bryant,1,4 Trevor A Sheldon,5 Derek Tuffnell,6 Su Golder,2 
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ABSTRACT
ObjeCtives
To assess the association between maternal glucose 
concentrations and adverse perinatal outcomes in 
women without gestational or existing diabetes and to 
determine whether clear thresholds for identifying 
women at risk of perinatal outcomes can be identified.
Design
Systematic review and meta-analysis of prospective 
cohort studies and control arms of randomised trials.
Data sOurCes
Databases including Medline and Embase were 
searched up to October 2014 and combined with 
individual participant data from two additional birth 
cohorts.
eligibility Criteria fOr seleCting stuDies
Studies including pregnant women with oral glucose 
tolerance (OGTT) or challenge (OGCT) test results, with 
data on at least one adverse perinatal outcome.
appraisal anD Data extraCtiOn
Glucose test results were extracted for OGCT (50 g) and 
OGTT (75 g and 100 g) at fasting and one and two hour 
post-load timings. Data were extracted on induction of 
labour; caesarean and instrumental delivery; 
pregnancy induced hypertension; pre-eclampsia; 
macrosomia; large for gestational age; preterm birth; 
birth injury; and neonatal hypoglycaemia. Risk of bias 
was assessed with a modified version of the critical 
appraisal skills programme and quality in prognostic 
studies tools.
results
25 reports from 23 published studies and two 
individual participant data cohorts were included, with 
up to 207 172 women (numbers varied by the test and 
outcome analysed in the meta-analyses). Overall most 
studies were judged as having a low risk of bias. There 
were positive linear associations with caesarean 
section, induction of labour, large for gestational age, 
macrosomia, and shoulder dystocia for all glucose 
exposures across the distribution of glucose 
concentrations. There was no clear evidence of a 
threshold effect. In general, associations were stronger 
for fasting concentration than for post-load 
concentration. For example, the odds ratios for large 
for gestational age per 1 mmol/L increase of fasting 
and two hour post-load glucose concentrations (after a 
75 g OGTT) were 2.15 (95% confidence interval 1.60 to 
2.91) and 1.20 (1.13 to 1.28), respectively. 
Heterogeneity was low between studies in all analyses.
COnClusiOns
This review and meta-analysis identified a large 
number of studies in various countries. There was a 
graded linear association between fasting and 
post-load glucose concentration across the whole 
glucose distribution and most adverse perinatal 
outcomes in women without pre-existing or 
gestational diabetes. The lack of a clear threshold at 
which risk increases means that decisions regarding 
thresholds for diagnosing gestational diabetes are 
somewhat arbitrary. Research should now investigate 
the clinical and cost-effectiveness of applying different 
glucose thresholds for diagnosis of gestational 
diabetes on perinatal and longer term outcomes.
systematiC review registratiOn
PROSPERO CRD42013004608
Introduction
Gestational diabetes, defined as hyperglycaemia first 
identified during pregnancy, increases the risk of a 
range of adverse perinatal outcomes including macro-
somia and caesarean section.1  There is also growing 
evidence that the longer term health of the mother and 
infant could be adversely affected.2-4  The primary aim 
of diagnosing gestational diabetes is to identify women 
and infants at risk of short or longer term adverse out-
comes. While traditionally the primary aim was to iden-
tify women at risk of type 2 diabetes, the recent 
International Association of Diabetes and Pregnancy 
Study Groups (IADPSG) proposed glucose thresholds 
WhAT IS AlReAdy knoWn on ThIS TopIC
Gestational diabetes (GDM) is associated with increased risk of a range of adverse 
perinatal outcomes and can affect the longer term health of mother and offspring
Treatment seems to reduce the risk of these outcomes, but the optimal glucose 
threshold to define gestational diabetes is unknown
Published thresholds for fasting and post-load glucose thresholds for diagnosing 
gestational diabetes are based on results from one multicentre study that considered 
large for gestational age, large skinfold thickness at birth, and cord blood C peptide)
Not all outcomes that pregnant women and clinicians would consider to be 
clinically important (including labour induction, caesarean section, neonatal 
hypoglycaemia, shoulder dystocia, and the need for neonatal intensive care) have 
been taken into account
WhAT ThIS STudy AddS
There is a consistent graded linear association between glucose concentrations and 
clinically relevant perinatal outcomes (caesarean section, induction of labour, large 
for gestational age, macrosomia, and shoulder dystocia), with no clear threshold
These patterns were robust to sensitivity analyses exploring the impact of study 
quality and type of glucose exposure and across geographical regions (studies from 
Asia, Australasia, Europe, North America and international (multicentre) studies)
There is currently no evidence from sub-Saharan Africa regarding the association 
between of gestational glucose and perinatal outcomes and little evidence from 
other low and middle income countries
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were calculated to identify adverse perinatal outcomes 
with the ultimate aim of preventing future obesity in 
offspring.5
Although treatment of gestational diabetes can 
reduce the risk of perinatal outcomes,6 7  there is uncer-
tainty regarding the optimal glucose threshold (at oral 
glucose tolerance testing (OGTT)) that should define 
gestational diabetes. Findings from the Hyperglycaemia 
and Adverse Pregnancy Outcomes (HAPO) study 
showed graded linear increases in large for gestational 
age, large skinfold thicknesses, high cord blood C pep-
tide, and several other important perinatal outcomes, 
across the whole distribution of fasting and post-load 
glucose in women without existing diabetes or gesta-
tional diabetes.8  Given the lack of any clear threshold 
for increased risk, the IADPSG calculated thresholds 
using the HAPO data as the glucose values at which 
odds for birthweight, cord C peptide, and percent body 
fat above the 90th centile reached 1.75 times the esti-
mated odds of these outcomes above mean glucose 
 values.5  The IADPSG criteria for diagnosing gestational 
diabetes have been endorsed by the World Health Orga-
nization (WHO)9  and more recently by the International 
Federation of Gynecology and Obstetrics (FIGO).10  Not 
all countries or institutions, such as UK National Insti-
tute of Health and Care Excellence (NICE)11  and Ameri-
can College of Obstetrics and Gynaecology,12 have 
endorsed these criteria. Though the HAPO study is 
large, multicentred, and well conducted, it did not pres-
ent results by country, and the shape and magnitude of 
the association between glycaemia and pregnancy out-
comes could differ in different populations, for example 
by ethnicity.
The question of whether the shape and magnitude of 
the association would be seen in all populations 
remains unanswered. We recently analysed a cohort of 
white British and south Asian women13 and found that 
the HAPO/IADPSG findings were replicated in the 
white British women, but in the south Asian women 
our results suggested that lower fasting and post-load 
glucose concentrations are required to achieve the 
same odds of identifying adverse perinatal outcomes. 
We also noted that the IADPSG thresholds for post-load 
glucose were importantly influenced by the fact that 
the post-load threshold used by HAPO to exclude 
women with gestational diabetes was much higher 
than that currently used in clinical practice and also at 
the time of the start of that study. A further issue is 
whether using a different set of outcomes would pro-
duce different diagnostic thresholds to those selected 
by the IADPSG, as, even with linear relations, the 
slopes are likely to differ and hence the threshold at 
which a given odds ratio would occur will differ 
between outcomes. In particular the IADPSG did not 
consider important clinical outcomes such as hyper-
tensive disorders of pregnancy, the requirement for 
induction of labour, caesarean section, and whether 
the infant suffered from shoulder dystocia, neonatal 
hypoglycaemia, and/or required admission to neonatal 
intensive care, which are key clinical criteria that clini-
cians and pregnant women are concerned about.
We conducted a systematic search of the literature to 
examine the available evidence and the degree to which 
these questions have been examined in different popu-
lations. Wherever possible we pooled data and con-
ducted appropriate sensitivity analyses to investigate 
any potential study and population effects.
Methods
We conducted this systematic review and meta-analysis 
in accordance with Cochrane Systematic Reviews14  and 
the Centre for Reviews and Dissemination recommen-
dations15 and have reported our findings according to 
PRISMA reporting guidelines.
search strategy
Searches were undertaken, and three reviewers (DF, MS 
and SG) independently assessed the literature for inclu-
sion. Data from eligible studies were combined with 
data from two additional birth cohort studies: the Born 
in Bradford cohort13 and the Atlantic Diabetes in Preg-
nancy cohort (F Dunne, personal communication), for 
which we also had access to individual participant data.
Identification of studies from systematic review
We searched the literature in September 2013 and 
 October 2014 using Medline and Medline in-Process, 
Embase, CINAHL Plus, the Cochrane Central Register 
of Controlled Trials (CENTRAL), Cochrane Database of 
Systematic Reviews (CDSR), Database of Abstracts of 
Reviews of Effects (DARE), Health Technology Assess-
ment database (HTA), NHS Economic Evaluation Data-
base (NHS EED), and Cochrane Methodology Register 
(CMR). The full Medline search strategy is shown in the 
appendix 1 and was appropriately translated for the 
other databases.
Identification of studies from unpublished individual 
participant data
We had access to three cohort studies with individual 
participant data: Born in Bradford (BiB; J Wright, 
 personal communication); Atlantic Diabetes in 
 Pregnancy (Atlantic-DIP; F Dunne, personal commu-
nication); and the Warwick/Coventry cohort 
(P   Saravanan, personal communication). The War-
wick/Coventry cohort had insufficient complete case 
data and was not included.
Born in Bradford is a prospective birth cohort; the 
study methods have been previously described.16  All 
women booked for delivery in Bradford are offered a 75 
g oral glucose tolerance test (OGTT) at around 26-28 
weeks’ gestation, and women were recruited mainly at 
their OGTT appointment.13  The Atlantic DIP is a multi-
centre cohort study comprising a partnership of five 
hospitals at the Irish Atlantic seaboard. It was set up in 
2006 with a focus on research, audit, clinical care, and 
professional and patient education for diabetes in preg-
nancy.17  As with the Bradford study, women were 
offered a 75 g OGTT at 24-28 weeks’ gestation from Sep-
tember 2006 to April 2012. Data on women with single-
ton pregnancies were collected from study entry until 12 
weeks’ postpartum.18
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study selection: inclusion and exclusion criteria
To be eligible, studies had to include pregnant women 
who had undergone an OGTT (comprising fasting and 
one, two, and three hour post-load samples) or oral glu-
cose challenge test (OGCT) (comprising a non-fasting 
and one hour post-load sample) with measures of fast-
ing and/or post-load glucose concentration. We 
excluded women from our analyses if they had pre- 
existing diabetes or had a diagnosis of gestational dia-
betes (using various criteria thresholds set by each 
included study; see table 1  for criteria and tables 2-4 for 
glucose thresholds) because they would have received 
treatment and this would have influenced the natural 
association between glucose and outcome. Studies had 
to provide data on at least one perinatal adverse out-
come in a form that could be included in the meta-anal-
yses (number of women and events in each glucose 
category).
Data extraction and quality assessment
Two reviewers (MS and SG) extracted data and con-
ducted the quality assessments. Any disagreements 
between reviewers were resolved through discussion, 
including with other authors as necessary. Risk of bias 
in the included studies was assessed with a modified 
version of the Critical Appraisal Skills Programme 
(CASP) and Quality in Prognostic Studies (QUIPS) 
assessment tools, designed for observational studies of 
association and prediction.48 When undertaking qual-
ity assessment of the studies, we considered the repre-
sentative nature of the included population; loss to 
follow-up; consistency of glucose measurement and 
outcome assessment; blinding of participants and med-
ical practitioners to glucose concentration; blinding of 
outcome assessors to glucose concentration; and selec-
tive reporting of outcomes. We also extracted informa-
tion on any adjustment for covariates, though our 
interest here is on a diagnostic threshold of glucose and 
in clinical practice this would not be adjusted for. We 
therefore aimed primarily to use unadjusted associa-
tions. Each criterion was classified as at low, high, or 
unclear risk of bias.
All of the studies reported numbers of women and 
numbers of adverse outcomes in a range of glucose cat-
egories. Data on these glucose categories (such as range 
and/or median concentration for each category, num-
bers of women and of outcomes in each category) were 
extracted for OGTT (75 g and 100 g test (fasting and one 
hour and two hour post-load)) and one hour 50 g OGCT. 
Data were extracted for the following perinatal out-
comes: induction of labour; caesarean section (elective 
or emergency); instrumental delivery (ventouse or for-
ceps); pregnancy induced hypertension (pre-eclamp-
sia; macrosomia (birthweight ≥4000 g); large for 
gestational age (≥90th birthweight centile); preterm 
birth (<37 weeks’ gestation); birth injury/trauma (shoul-
der dystocia, Erb’s palsy, fractured clavicle), and 
 neonatal hypoglycaemia. We also extracted sociodemo-
graphic and clinical data, such as age range of partici-
pants, how those with diabetes were excluded, and 
parity.
For the two studies with individual participant data 
we created seven categories of glucose concentration 
for both fasting and two hour post-load glucose concen-
trations, designed to include approximately equal num-
bers of women in each category. The numbers of women 
and numbers of adverse outcomes in each category 
were then calculated for each outcome to generate sum-
mary data similar to that extracted from publications.
statistical analysis
Analyses were based on the number of women and 
number of adverse perinatal outcomes in each glucose 
category in each study. Use of these raw numbers means 
that we did not adjust our results for any covariates. Our 
aim, however, was to determine whether there were 
clear glucose thresholds for diagnosis of gestational 
diabetes across a range of pregnancy and perinatal out-
comes and not to assess causality. Thus, confounding is 
not a concern and reflects clinical practice (where glu-
cose thresholds without adjustment are used) and the 
lack of any adjustment for covariates is therefore appro-
priate here. We explored whether results were heteroge-
neous and, if so, whether this related to characteristics 
that differ between participants in the different studies, 
which was relevant to our aim of determining whether 
the HAPO/IADPSG results were generalisable.
One study44 presented only adjusted odds ratios 
(adjusted for maternal age, gestational age at enrol-
ment and at delivery, parity, BMI, and race or ethnicity). 
With the exception of that one study all other results 
from all other studies were the unadjusted associations 
that we required.
To determine whether any glucose threshold exists 
above which women or infants are at significantly 
greater risk of adverse perinatal outcomes, we tested 
the validity of the assumption of a log-linear associa-
tion between outcome and glucose concentration by 
visual assessment (based on plotting the results from 
each study and by using a model with an additional 
“glucose-squared” term. A significant association with 
glucose squared would suggest a quadratic-curvilinear 
association.
table 1 | recommended criteria for diagnosis of gestational diabetes with oral glucose 
tolerance test (Ogtt)
fasting
One hour 
post-load
two hour 
post-load
three hour 
post-load
75 g Ogtt (plasma glucose)
IADPSG5 (2010), ADIPS (2013), WHO9 (2013)* ≥5.1 ≥10.0 ≥8.5 —
WHO19 (1999)* ≥6.1 — ≥7.8 —
ADA20 (2006)* ≥5.3 ≥10.0 ≥8.6 —
ADIPS21 (1998)* ≥5.5 — ≥8.0 —
100 g Ogtt (plasma or serum glucose)
ACOG12/C-C† ≥5.3 ≥10.0 ≥8.6 ≥7.8
NDDG22† ≥5.8 ≥10.6 ≥9.2 ≥8.0
O’Sullivan23† ≥5.0 ≥9.2 ≥8.1 ≥6.9
IADPSG=International Association of Diabetes and Pregnancy Study Groups; ACOG=American College of 
Obstetricians and Gynecologists; ADIPS=Australasian Diabetes in Pregnancy Society; ADA=American Diabetes 
Association; C&C=Carpenter & Coustan criteria24; NDDG=National Diabetes Data Group; WHO=World Health 
Organization.
*One threshold should be equalled or exceeded for diagnosis of gestational diabetes.
†Two thresholds should be equalled or exceeded for diagnosis of gestational diabetes.
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After our initial visual assessment of glucose and 
perinatal outcome plots, we modelled associations 
across studies in a “one stage” hierarchical logistic 
regression analysis.49 The numbers of women with an 
outcome event in each glucose category was regressed 
against the average glucose concentration in each cate-
gory. Independent intercepts and random effects on the 
slopes across studies were included to allow the base-
line risk and the association between glucose concen-
tration and outcome to vary between studies, thus 
accounting for any potential heterogeneity. We used 
mixed effects logistical regression routines in R soft-
ware for the modelling. We assessed the percentage of 
variance between study findings not due to chance by 
determining the I2 statistic.14 When an outcome was 
reported in only one study, we fitted the same logistic 
regression model but without the meta-analysis compo-
nent to estimate the association between outcome and 
glucose concentration as for outcomes reported by sev-
eral studies.
Associations were modelled separately for each out-
come, glucose test (75 g OGTT, 100 g OGTT, 50 g OCGT), 
and timing of the measurement of glucose concentra-
tion (fasting and one hour or two hour post-load). These 
models produced a summary estimate across studies 
for the association between concentration and outcome 
in terms of the odds ratio of outcome per 1 mmol/L 
increase in concentration. Full details of the statistical 
methods and models are provided in appendix 2.
To increase the number of studies and participants 
we combined the fasting glucose results from the 75 g 
and 100 g OGTT in meta-analyses using the logistic 
regression models described above because fasting glu-
cose should not be affected by the subsequent glucose 
test load (75 g or 100 g). We also combined the 75 g and 
100 g one hour post-load results and the 75 g and 100 g 
two hour post-load results, assuming the associations 
between glucose and outcomes were the same for 
both tests.
We conducted two sensitivity analyses, one that 
excluded studies with a high or unclear risk of surveil-
lance and detection bias (lacked blinding) from analy-
ses (leaving four published reports related to two 
studies8 32 36 50). We also examined the influence of study 
population/region of residence on estimates using the 
75 g and 100 g OGTT by dividing studies into five catego-
ries (international, North America, Europe, Asia, 
 Australasia) and repeating the meta-analyses within 
each region. These regions were chosen once we had 
completed our search and are based on identified 
 relevant studies.
patient involvement
As this is a systematic review and meta-analyses using 
conventional methods we did not seek the views of 
women in the design or conduct of our study. The out-
comes we included in this review were those identified 
by the Cochrane Pregnancy and Childbirth Group 
(CPCG) as being essential for reviews of diabetes in 
pregnancy. The CPCG includes relevant patients/service 
users (in this case women of reproductive age and/or t
ab
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women who have had gestational diabetes) who con-
tribute to decisions about which outcomes are included 
in the standard list.
Results
Details of included and excluded studies
Figure 1  shows the number of reports and studies iden-
tified and numbers included and excluded. After 
screening titles and abstracts, we obtained 125 study 
reports for full text review. After full text review we 
included 25 published reports detailing associations 
between perinatal outcomes and maternal glucose con-
centrations. At title and abstract screening, studies 
were excluded mainly because they were not answering 
the question we were examining. At full text screening, 
studies were excluded mostly because they did not 
present data (conference abstracts), did not report any 
of our included outcomes, did not report outcomes by 
glucose concentrations, or did not report data in a form 
that could be included or converted for inclusion in the 
meta-analyses. Published studies were combined with 
the two individual participant data cohorts; BiB and 
Atlantic DIP. Tables 2, 3, and 4 summarise the character-
istics of the included publications and individual par-
ticipant data cohorts.
Quality assessment
Generally, studies had a low risk of bias (table A, appen-
dix 3), with the exception of surveillance and detection 
bias, which was high or unclear for all but four pub-
lished reports related to two studies. Most studies 
recruited any pregnant women without pre-existing 
diabetes or newly diagnosed gestational diabetes, often 
at the study hospital’s gestational diabetes screening 
clinic. Few studies applied any further inclusion/exclu-
sion criteria so the study populations’ are likely to be 
representative of the general obstetric population at the 
study site. Studies generally did not report comprehen-
sive demographic details of participants and did not 
report results by subgroups, including by ethnicity. In 
studies that included a proportion of women with ges-
tational diabetes and reported outcomes separately, we 
extracted only data for those without gestational diabe-
tes. Most studies were in Western populations from high 
income countries, with a small number from other pop-
ulations, such as the Pima Indian population of Ari-
zona. Most studies had minimal loss to follow-up. 
Studies diagnosed gestational diabetes (and excluded 
women) with both the one and two step approach with 
either the 75 g or 100 g OGTT and with various glucose 
thresholds (tables 3 and 4).
The main potential risk of bias was due to lack of 
blinding of glucose concentrations after OGTT. This 
could have resulted in surveillance or detection bias (and 
potentially to a self fulfilling prophesy). For example, 
pregnancy surveillance might have been increased in 
women with higher glucose concentrations, which could 
have increased the likelihood of interventions including 
induction of labour or caesarean section or the scrutiny 
with which other outcomes are determined, compared 
with surveillance in women with lower concentrations.
linear associations of glucose with perinatal 
outcomes
Figure 2 shows the pooled results for the association 
between increases in fasting glucose and results of one 
hour post-load 50 g OGCT, two hour 75 g OGTT, and two 
hour 100 g OGTT and each perinatal outcome.
For all glucose exposures there were positive associa-
tions with caesarean section, induction of labour, large 
for gestational age, macrosomia, and shoulder  dystocia. 
In general for these outcomes, the magnitudes of asso-
ciation were stronger for fasting glucose compared with 
any of the post-load glucose measurements. For exam-
ple, the odds ratios for large for gestational age per 1 
mmol/L increase of fasting and two hour post-load glu-
cose concentrations (after a 75 g OGTT) were 2.15 (95% 
confidence interval 1.60 to 2.91) and 1.20 (1.13 to 1.28), 
respectively (figure C, appendix 3). Increases in fasting 
glucose concentration was also clearly inversely associ-
ated with preterm delivery, whereas the association 
between post-load concentration and this outcome was 
more inconsistent: weakly positive for 50 g one hour 
OGCT, weakly positive for 75 g two hour OGTT, and 
inverse with 100 g two hour OGTT; but for some of 
these, particularly the latter, the confidence intervals 
were wide and included the null. We found that results 
of 50 g one hour post-load OGCT and 75 g two hour 
OGTT were positively associated with instrumental 
delivery, whereas fasting glucose concentration was not 
clearly associated with this outcome (no studies using a 
100 g OGTT reported this outcome). All glucose mea-
surements, except the two hour 100 g post-load glucose 
concentration from the OGTT, were positively associ-
ated with neonatal hypoglycaemia. The 75 g two hour 
post-load OGTT result was positively associated with 
combined pregnancy induced hypertension/pre-ec-
lampsia, but there was no consistent association 
between results of the 50 g OGCT or 100 g two hour post-
load OGTT and this outcome.
When we pooled two hour post-load glucose associa-
tions with outcomes for studies that used either a 75 g or 
a 100 g OGTT, the pattern of associations were broadly 
similar to those when the two sets of studies were con-
sidered separately (fig A, appendix 3).
Additional records identied through other
sources such as reference checking (n=22)
Potentially relevant records identied
through database searching (n=15 916)
Records screened aer duplicates removed (n=11 241)
Full text reports assessed for eligibility (n=125)
Included (n=25 published reports from 23 studies, plus 2 IPD cohorts)
Records excluded (n=11 113)
Individual participant data cohorts (n=2)
Full text reports excluded (n=100)
fig 1 | flow diagram for selection of studies of hyperglycaemia and risk of adverse perinatal 
outcomes
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Associations between glucose concentrations and 
outcomes were generally monotonic, suggesting linear 
associations across the distribution with no clear 
threshold at which risk substantially increases (figs A-I, 
appendix 4). The quadratic statistical tests largely sup-
ported the linear association, with some possible flat-
tening of the positive association with pregnancy 
induced hypertension combined with pre-eclampsia or 
pre-eclampsia alone at the upper end of the post-load 
glucose distribution (table B, appendix 3). Few studies 
assessed one hour post-load glucose concentration for 
either 75 g or 100 g OGTT, and only a subset of the 
 outcomes were examined in those studies for this 
 exposure. In general results for the one hour post-load 
concentration were broadly similar to those for the two 
hour post-load concentration, but, given the limited 
amount of data for these associations, estimates were 
less precise with wider confidence intervals.
sensitivity and subgroup analyses
Figures K and L in appendix 3 show the pooled results 
for the association between fasting and two hour post-
load glucose concentration (75 g OGTT ) and each peri-
natal outcome, excluding all results from the two 
studies (four published reports) that were least likely to 
have bias because of lack of blinding.
Our analyses were limited by the fact that there were 
only two studies for which we could ascertain that clin-
ical staff were definitely blinded, one of which was the 
largest study included in the whole meta-analyses.8 
Broadly, results for fasting glucose and two hour post-
load concentrations were similar between studies with 
definite blinding and those without blinding or where 
we were unsure (figs K and L, appendix 3). The associa-
tion between fasting glucose concentration, but not two 
hour post-load concentration, and birth size (both large 
for gestational age and macrosomia), but not other out-
comes, seemed stronger for the blinded studies (large 
for gestational age8  and macrosomia32) than all other 
studies pooled together.
Exclusion of studies with blinding left data from only 
one study examining the association between fasting 
glucose concentration and neonatal hypoglycaemia. 
This study included 2904 women and showed a positive 
association, with point estimates that were higher than 
those in the main meta-analysis without these exclu-
sions (odds ratio 1.43 (95% confidence interval 0.64 to 
3.22) and 1.37 (1.20 to 1.57), respectively).37 Because of 
the small sample size of this one study, however, the 
confidence intervals were wide and included the null 
result. The only other study with this outcome at fasting 
was HAPO, and the results from that study (based on 
the point estimate) suggested a possible weaker associ-
ation, but the results from the two studies are consis-
tent with each other (odds ratio 1.37 (1.20 to 1.57) for 
HAPO alone). Similarly, after exclusions only two stud-
ies with 3191 women remained for the two hour post-
load association with neonatal hyperglycaemia. The 
point estimates were the same as the main analyses, 
though, again because of the reduced sample size, the 
confidence intervals were wide and included the 
null result.
We examined the effect of region on the association 
between fasting concentration and two hour post-load 
concentration (75 g OGTT) and each perinatal outcome 
(figs M and N, appendix 3). These results suggest that 
the positive linear associations seen when we combined 
all studies were also present across each of the regions 
we were able to examine. There is some suggestion that 
the magnitude of the associations varies by region for 
some outcomes where these were assessed in several 
regions. Specifically, the associations with large for ges-
tational age seemed weakest in studies from Asian 
regions and strongest in studies that were international 
Combined 75 g and 100 g - Fasting
  C section
  Induction
  Instrumental birth
  LGA
  Macrosomia
  Neonatal hypoglycemia
  PIH/pre-eclampsia
  Pre-eclampsia
  Preterm birth
  Shoulder dystocia
50 g OGCT
  C section
  Induction
  Instrumental birth
  LGA
  Macrosomia
  Neonatal hypoglycemia
  PIH/pre-eclampsia
  Pre-eclampsia
  Preterm birth
  Shoulder dystocia
Two hour post-load 75 g OGTT
  C section
  Induction
  Instrumental birth
  LGA
  Macrosomia
  Neonatal hypoglycemia
  PIH/pre-eclampsia
  Pre-eclampsia
  Preterm birth
  Shoulder dystocia
Two hour post-load 100 g OGTT
  C section
  LGA
  Macrosomia
  Neonatal hypoglycemia
  PIH/Ppre-eclampsia
  Pre-eclampsia
  Preterm birth
  Shoulder dystocia
1.59 (1.49 to 1.70)
1.31 (1.14 to 1.50)
0.99 (0.87 to 1.13)
2.11 (1.73 to 2.58)
2.06 (1.86 to 2.28)
1.37 (1.2 to 1.57)
1.91 (1.49 to 2.43)
2.15 (1.45 to 3.19)
0.77 (0.62 to 0.96)
1.97 (1.36 to 2.85)
1.39 (1.18 to 1.64)
1.30 (1.20 to 1.41)
1.14 (1.04 to 1.23)
1.28 (1.21 to 1.36)
1.13 (1.10 to 1.15)
1.16 (1.05 to 1.28)
1.02 (0.75 to 1.38)
1.18 (1.13 to 1.23)
1.04 (1.00 to 1.08)
1.25 (1.10 to 1.43)
1.11 (0.93 to 1.31)
1.10 (1.04 to 1.16)
1.07 (1.03 to 1.12)
1.21 (1.18 to 1.24)
1.19 (1.14 to 1.25)
1.13 (1.09 to 1.18)
1.21 (1.08 to 1.35)
1.23 (1.18 to 1.28)
1.07 (0.99 to 1.15)
1.32 (1.14 to 1.52)
1.14 (1.04 to 1.25)
1.35 (1.17 to 1.55)
1.29 (1.15 to 1.44)
1.09 (0.66 to 1.80)
1.14 (0.96 to 1.35)
1.37 (1.14 to 1.65)
0.87 (0.41 to 1.87)
1.56 (1.21 to 1.99)
0
0
0
1
0
0
0
5
0
0
6
0
0
0
0
0
0
0
0
0
22
0
0
0
0
0
0
0
0
0
0.5 1 2 3
Outcome Odds ratio
(95% CI)
Odds ratio
(95% CI)
I2
(%)
6
2
3
7
6
2
3
4
3
4
7
1
2
4
7
3
1
6
2
2
7
2
4
9
5
2
2
3
5
3
2
2
2
1
1
1
1
2
No of
studies
47 746
12 484
17 257
46 680
28 303
19 998
5551
39 345
17 257
18 615
36 616
13 902
3791
30 626
64 851
15 619
1157
58 270
27 126
27 688
41 130
12 485
18 661
48 321
19 524
19 998
4174
35 720
18 816
17 260
3915
1645
3877
287
1358
3628
249
1645
No of
women
fig 2 | Odd ratios for outcomes associated with glucose concentration (fasting combined 
75 g and 100 g Ogtt, one hour post-load 50 g OgCt, two hour post-load 75 g Ogtt, and two 
hour post-load 100 g Ogtt)
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or from North America, with those from Australasia and 
Europe in between. But, given the reduced sample sizes 
within these stratified analyses, it is not possible to 
determine whether these differences are due to chance.
Heterogeneity between studies
Figures B-J in appendix 3 show the individual forest 
plots for each association for fasting, one hour 50 g 
OGCT post-load, and two hour 75g OGTT. The I2 statistic 
for heterogeneity between the studies for most of the 
associations was low or 0 (fig 2 and fig A, appendix 3).
discussion
In pregnant women without existing diabetes or gesta-
tional diabetes mellitus, there are positive linear associ-
ations between fasting and post-load glucose 
concentrations (after 50 g, 75 g, and 100 g loads) and 
most adverse perinatal outcomes—including caesarean 
section, induction of labour, large for gestational age, 
macrosomia, and shoulder dystocia. In general, associ-
ations between fasting glucose concentrations and 
these outcomes were stronger than those of post-load 
concentrations. Fasting glucose concentration was 
inversely associated with preterm delivery, but there 
was no strong evidence of a clear association between 
post-load concentration and this outcome. In most 
studies the clinician caring for the woman was likely to 
have known her glucose concentration and so the find-
ings could have been biased by surveillance/detection 
bias. When we excluded two studies with four reports in 
which there was blinding (including the largest and 
potentially most influential study), however, the results 
were similar to when we included all studies. When we 
explored associations by geographical region (Asia, 
Australasia, Europe, international, and North-America) 
they showed the same linear pattern of association. 
Though the 50 g OGCT is not administered after an over-
night fast, which invariably introduces a greater degree 
of variability, we found the same linear associations 
with this test as with the more controlled 75 g and 100 g 
OGTT (which are administered after an overnight fast). 
Thus, our results are robust to different sensitivity anal-
yses based on study quality, population, and type of 
glucose test. The similarity of results from an OGCT to 
those from the OGTT suggest that in populations that 
find fasting difficult, this test could provide some indi-
cation of a woman’s response to glucose and the degree 
of associated risk, though it is important to note that 
there were relatively few studies for this test and no 
data available for some of our outcomes.
This detailed systematic review and large scale 
meta-analysis provides no clear glucose threshold to 
define gestational diabetes above which risk increases 
notably across a wide range of clinically relevant preg-
nancy and perinatal outcomes. The recent IADPSG cri-
teria acknowledged the need to arbitrarily define a 
threshold for diagnosis. They based this on the point 
(for fasting, one hour, and two hour post-load 75 g 
OGTT) at which glucose concentrations above the mean 
resulted in an odds ratio of at least 1.75 but considered 
only three outcomes—large for gestational age, large 
skinfold thickness at birth, and cord blood C peptide. 
These do not include key clinical outcomes, including 
the need for induction, caesarean section, neonatal 
hypoglycaemia, shoulder dystocia, and admission to 
neonatal intensive care, that obstetricians, midwives, 
and pregnant women consider important.51 Thus, our 
results show linear associations without thresholds 
across a range of different populations, with different 
glucose tests, and for clinically relevant outcomes.
We found no strong evidence of heterogeneity, with 
low to negligible I2 results for all tests. This further sup-
ports the robustness of our findings across a wide range 
of populations, though we acknowledge that our find-
ings would not necessarily generalise to populations in 
low and middle income countries for which there is lit-
tle relevant information.
We did not apply the IADPSG odds ratio of 1.75 to 
define glucose thresholds for gestational diabetes 
across the wider range of perinatal outcomes explored 
here for several reasons. Firstly, 1.75 is arbitrary, and we 
think a range of thresholds ought to be considered. Sec-
ondly, application of one odds ratio to all of our out-
comes would assume that they are all equally clinically 
important. But would clinicians and parents consider 
induction of labour to be as important as shoulder dys-
tocia or an infant requiring neonatal intensive care? The 
three outcomes that IADPSG used to define thresholds 
for gestational diabetes (large for gestational age, large 
thickness skinfold at birth, and cord blood C peptide) 
were all concerned with the same broad concept of 
infant adiposity and markers of future risk of obesity in 
the offspring and so application of the same odds ratio 
to each of these might be appropriate, but we do not 
believe it is for the range of outcomes we have examined 
here. Thirdly, we consider the results from this review 
should be combined with relevant evidence of treat-
ment effects and economic evaluations, as well as con-
sideration of whether different levels of risk should be 
applied to different outcomes, to define the optimal 
clinical and cost-effective thresholds.
strengths and limitations
This systematic review and meta-analysis included 
many studies with varied populations and provides the 
largest sample of women in whom these associations 
have been examined. We intentionally had broad inclu-
sion criteria so that we could explore any heterogeneity 
between study populations and make conclusions rele-
vant to most pregnant women. We found no evidence of 
heterogeneity overall, but it should be noted that most 
women came from high income countries. Thus our 
findings are not necessarily generalisable to lower 
income settings. Though we wanted to examine the 
influence of ethnicity on associations, most studies did 
not provide the detail to allow this. While we found sim-
ilar patterns of association by geographical region we 
cannot assume that this reflects ethnicity. For example, 
the UK Born in Bradford cohort, includes about half 
white British and half south Asian women.
One of the main limitations of the individual studies 
was the lack of definite blinding of those who were 
the bmj | BMJ 2016;354:i4694 | doi: 10.1136/bmj.i4694
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looking after the pregnant women to the OGTT fasting 
and post-load glucose concentrations. This could bias 
the magnitudes of the association towards the null if 
carers provided advice (about diet for example) or even 
treatment with oral hypoglycaemics to those women 
who had borderline high glucose concentrations that 
did not quite reach the diagnostic criteria for excluding 
women with gestational diabetes. We tried to explore 
this in sensitivity analyses of pooled results in those 
studies that had definitely blinded clinical staff com-
pared with those that had not blinded staff or for which 
it was unclear whether or not they had blinded them. In 
general results looked similar in the two groups. Only 
two studies, however, had definitely blinded staff, and 
one of these was the largest study—HAPO. The strong 
associations between fasting glucose concentrations 
and large for gestational age and macrosomia in the 
blinded studies compared with other studies could 
reflect blinding, but it could also be a chance finding 
considering the number of comparisons undertaken in 
this sensitivity analysis. Given that this analysis is com-
paring just one or two studies with all others it could 
also be driven by other differences. Importantly, the dif-
ference is small and does not alter our overall conclu-
sion regarding the linear dose-response nature of the 
associations between glucose concentrations and a 
wide range of clinically important perinatal outcomes.
The inclusion of women with a diagnosis of gestational 
diabetes would have affected the estimates of the associ-
ation between glucose concentration and outcomes as 
these women would be treated to reduce their concentra-
tion; they were therefore excluded. Although we found no 
evidence of a curvilinear association between glucose 
and outcomes at concentrations below current treatment 
thresholds, the possibility exists that risks might increase 
substantially at concentrations exceeding them.
The increased identification of women resulting from 
lowering glucose thresholds to diagnose gestational dia-
betes has resource implications for maternity services in 
terms of antenatal care (OGTTs, treatments, induction of 
labour), intrapartum care (caesarean section), and short 
and longer term postnatal care (infant care, screening 
for type 2 diabetes). Costs are likely to be greater for 
identification and treatment strategies that use lower 
glucose thresholds if care packages are unchanged. 
Because there is a graded linear association between 
maternal glucose concentration and risk of perinatal 
outcomes, risk of these outcomes could be reduced if 
thresholds are lowered. There are no trials using these 
new thresholds, however, and no robust evidence that 
the longer term risk of obesity would be improved.52
recommendations for research
Considering all eligible evidence, it is clear that the 
association between glucose concentration and a wide 
range of clinically relevant adverse perinatal outcomes 
is linear and that there is no threshold above which 
odds substantially increase in high income countries. 
With the exception of large well conducted studies in 
low and middle income countries, we recommend that 
further studies of the nature of the association of 
 gestational glucose with perinatal outcomes are not 
required. We believe that studies in low and middle 
income countries are important, and this might be par-
ticularly the case for sub-Saharan Africa, where there 
seems to have been no studies to date but where the 
prevalence of  diabetes is increasing and possibly has a 
different phenotype to that seen in Western high income 
countries and where perinatal outcomes also have dif-
ferent  presentations.53 54  Also there are few studies in 
South Asia, but again diabetes is an increasing problem 
here and could influence perinatal outcomes in a differ-
ent way to that seen in European origin populations, as 
suggested by our earlier results in Born in Bradford.13
As noted above, rather than apply an arbitrary level 
of risk, such as an odds ratio of 1.75, to all of the clini-
cally relevant outcomes we have examined here, we 
believe that future research needs to combine our 
results with robust evidence from well conducted ran-
domised trials (and meta-analyses of those) of treat-
ment effects on adverse outcomes related to gestational 
diabetes. Economic evaluations and research are 
required to determine what relative importance women, 
their partners, and care givers attribute to the different 
outcomes to determine the level at which clinical and 
cost effectiveness is maximised.
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